Prevalence of genital human papillomavirus in males, United States, 2013-2014

Journal of Infectious Diseases

Volumn 215, Issue 7, 2017, Pages 1070-1079

  Gargano, Julia W ^a   Unger, Elizabeth R ^b   Liu, Gui ^a   Steinau, Martin ^b   Meites, Elissa ^a   Dunne, Eileen ^c   Markowitz, Lauri E ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Epidemiology; Herd immunity; Human papillomavirus; Sexually transmitted infections; Vaccine impact

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

ADOLESCENT; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; GROUPS BY AGE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT INFECTION; PAPILLOMAVIRUS INFECTION; PENILE BIOPSY; PREVALENCE; PRIORITY JOURNAL; RACE; SEXUAL BEHAVIOR; UNITED STATES; VACCINATION; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; NUTRITION; PAPILLOMAVIRIDAE; RISK FACTOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 85020209481     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix057     Document Type: Conference Paper

References (48)

1. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7:453-9.
2. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health 2011; 48:540-52.
3. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43:S5-25, S25.e1-41.
4. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 Suppl 5:F55-70.
5. Bouvard V, Baan R, Straif K, et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10:321-2.
6. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5:F12-23.
7. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015; 107:djv086.
8. Centers for Disease C, Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-8.
9. Markowitz LE, Dunne EF, Saraiya M, et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1-30.
10. Dunne EF, Sternberg M, Markowitz LE, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health and Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? J Infect Dis 2011; 204:562-5.
11. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204:566-73.
12. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93.
13. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137:e20151968.
14. Hebnes JB, Munk C, Nøhr B, et al. Human papillomavirus infection among 2460 men in Denmark: prevalence in relation to age using 2 human papillomavirus DNA testing methods. Sex Transm Dis 2015; 42:463-7.
15. Johnson AM, Mercer CH, Beddows S, et al. Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect 2012; 88:212-7.
16. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827-35.
17. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196:1128-36.
18. Meites E, Gorbach PM, Gratzer B, et al. Monitoring for human papillomavirus vaccine impact among gay, bisexual, and other men who have sex with Men- United States, 2012-2014. J Infect Dis 2016; 214:689-96.
19. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2036-43.
20. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377:932-40.
21. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National Health and Nutrition Examination Survey: sample design, 2011-2014. Vital Health Stat 2 2014; Mar:1-33.
22. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES): MEC interviewers procedure manual. http://www.cdc.gov/nchs/data/nhanes/nhanes-13-14/MEC-Interviewer-2013.pdf.Accessed 22 July 2016.
23. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: interviewer procedures manual. https://www.cdc.gov/nchs/data/nhanes/nhanes-13-14/Intrvwr-Proc-Manual.pdf. Accessed 12 July 2016.
24. Xu F, Markowitz LE, Sternberg MR, Aral SO. Prevalence of circumcision and herpes simplex virus type 2 infection in men in the United States: the National Health and Nutrition Examination Survey (NHANES), 1999-2004. Sex Transm Dis 2007; 34:479-84.
25. Hernandez BY, Wilkens LR, Unger ER, et al. Evaluation of genital self-sampling methods for HPV detection in males. J Clin Virol 2013; 58:168-75.
26. Onyekwuluje JM, Steinau M, Swan DC, Unger ER. A real-time PCR assay for HPV52 detection and viral load quantification. Clin Lab 2012; 58:61-6.
27. Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital Health Stat 2 2013; Sep:1-24.
28. Steinau M, Hariri S, Gillison ML, et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 2014; 209:1739-43.
29. Gravitt PE, Rositch AF, Silver MI, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013; 207:272-80.
30. Edelstein ZR, Carter JJ, Garg R, et al. Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis 2011; 204:209-16.
31. Taylor S, Bunge E, Bakker M, Castellsagué X. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature. BMC Infect Dis 2016; 16:293.
32. Akogbe GO, Ajidahun A, Sirak B, et al. Race and prevalence of human papillomavirus infection among men residing in Brazil, Mexico and the United States. Int J Cancer 2012; 131:E282-91.
33. Gray RH, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1455-62.
34. Kong X, Archer KJ, Moulton LH, Gray RH, Wang MC. Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance. BMC Med Res Methodol 2010; 10:40.
35. Serwadda D, Wawer MJ, Makumbi F, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1463-9.
36. Albero G, Castellsagué X, Giuliano AR, Bosch FX. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis 2012; 39:104-13.
37. Albero G, Castellsagué X, Lin HY, et al. Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study. BMC Infect Dis 2014; 14:75.
38. Giuliano AR, Lazcano E, Villa LL, et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer 2009; 124:1251-7.
39. Nielson CM, Schiaffino MK, Dunne EF, Salemi JL, Giuliano AR. Associations between male anogenital human papillomavirus infection and circumcision by anatomic site sampled and lifetime number of female sex partners. J Infect Dis 2009; 199:7-13.
40. Weaver BA, Feng Q, Holmes KK, et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004; 189:677-85.
41. Goldstone S, Palefsky JM, Giuliano AR, et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis 2011; 203:66-74.
42. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis 2011; 203:49-57.
43. Vriend HJ, Bogaards JA, van der Klis FR, et al.; Medical Microbiological Laboratories, Municipal Health Services. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One 2013; 8:e60696.
44. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-5.
45. Chow EP, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis 2016.
46. Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One 2015; 10:e0132404.
47. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
48. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years- United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:784-92.